Compare NRG Energy Inc (NRG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Regeneron Pharmaceuticals Inc — how do they compare? NRG Energy Inc trades at $108.49 (market cap $22.35B), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.4× NRG Energy Inc's market cap, and NRG Energy Inc pays the higher dividend (1.79%). Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 62 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| NRG | REGN | |
|---|---|---|
Market Cap | $22.35B | $76.14B |
Volume | 5,011,942 | 500,239 |
Sector | Utilities | Health |
52-Week High | $184.03 | $852.03 |
52-Week Low | $95.23 | $557.73 |
Typical Hold Time | 62 Days | 107 Days |
Enterprise Value | $46.30B | $70.85B |
Dividend Yield | 1.79% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy (NRG) trades at $108.61, up 4.84% today, with a bullish technical signal and strong analyst consensus. Recent earnings showed a Q2 2026 miss but the company is executing a growth strategy including a 1.2 GW Texas data-center power project. Financials indicate solid revenue of $30.71B in 2025, though net margins are thin at 2.56%, and cash flow trends are volatile with a projected net outflow in 2026.
The outlook is positive given high analyst buy ratings and a $202.90 price target, but risks include execution on large capital projects, rising debt levels, and competitive pressures. Earnings growth from new assets and customer relationships remains the key catalyst for upside, though the stock faces near-term volatility from recent misses.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
